Vertaling van "prevention in elderly patients with atrial " (Frans → Nederlands) :

Garcia D et Hylek E: Stroke prevention in elderly patients with atrial fibrillation.
Garcia D en Hylek E: Stroke prevention in elderly patients with atrial fibrillation.

Hylek EM, Evans-Molina C, Shea C, Henault LE et Regan S: Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation.
Hylek EM, Evans-Molina C, Shea C, Henault LE en Regan S: Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation.

randomized trials.1 Effective strategies for the secondary prevention of stroke include treatment of hypertension and hyperlipidemia, antithrombotic therapy for patients with atrial fibrillation, and antiplatelet therapy (Evidence level 1). 1 Statins are effective in the prevention of stroke, although evidence remains limited to heart disease patients (Evidence level 1). 2, 3
treatment of hypertension and hyperlipidemia, antithrombotic therapy for patients with atrial fibrillation, and antiplatelet therapy (Evidence level 1).1 Statins are effective in the prevention of stroke, although evidence remains limited to heart disease patients (Evidence level 1).2, 3

For primary prevention of stroke, adequate blood pressure reduction, and treatment of hyperlipidemia, use of antithrombotic therapy in patients with atrial fibrillation and of antiplatelet therapy in patients with myocardial infarction are effective and supported by evidence from several
For primary prevention of stroke, adequate blood pressure reduction, and treatment of hyperlipidemia, use of antithrombotic therapy in patients with atrial fibrillation and of antiplatelet therapy in patients with myocardial infarction are effective and supported by evidence from several randomized trials.1 Effective strategies for the secondary prevention of stroke include

van Gelder IC, Hagens VE, Bosker HA et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002; 347:1834-40. de Denus S, Sanoski CA, Carlsson J et al. Rate vs rhythm control in patients with atrial fibrillation: a meta-analysis.
de Denus S, Sanoski CA, Carlsson J et al. Rate vs rhythm control in patients with atrial fibrillation: a meta-analysis.

Hart RG, Pearce LA et Aguilar MI: Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation.
Hart RG, Pearce LA en Aguilar MI: Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation.

D’après Camm AJ et Savelieva I. Some patients with paroxysmal atrial fibrillation should carry flecainide or propafenone to self treat.
Naar Camm AJ en Savelieva I. Some patients with paroxysmal atrial fibrillation should carry flecainide or propafenone to self treat.

32. Kastrup A, Schulz JB, Raygrotzki S, Groschel K, Ernemann U. Comparison of angioplasty and stenting with cerebral protection versus endarterectomy for treatment of internal carotid artery stenosis in elderly patients.
angioplasty and stenting with cerebral protection versus endarterectomy for treatment of internal carotid artery stenosis in elderly patients.

J. Med. 340, 138-139 (1999) Cummings P.I. : Antibiotics to prevent infection in patients with dog bite wounds: a meta-analysis of randomised trials.
Med. J. 314, 88 (1997) Williams D.N. en Kaur B.: Postsplenectomy care.

Dans l’étude JPAD (Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes), une étude randomisée ouverte, ayant inclus des patients diabétiques de type 2 sans antécédents d’affection vasculaire, l’administration d’acide acétylsalicylique (81 ou 100 mg p.j) n’a pas non plus diminué le risque cardio-vasculaire, ni la mortalité [ JAMA 2008; 300: 2134-41 avec un éditorial : 2180-1 ].
In de JPAD-studie (Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes), een gerandomiseerde open studie bij patiënten met type 2-diabetes zonder antecedenten van een vasculaire aandoening, werd met acetylsalicylzuur (81 of 100 mg p.d) evenmin een daling van het cardiovasculaire risico of van de mortaliteit gezien [ JAMA 2008; 300: 2134-41 met editoriaal : 2180-1 ].